BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR AND Treatment
1332 results:

  • 1. Case report: Preventive infusion of donor-derived CD7 chimeric antigen receptor T cells after allogeneic hematopoietic stem cell transplantation.
    Jiang Y; Feng D; Zhu J; Wei D; Zhao C; Liu H; Shao S; Wang C
    Front Immunol; 2024; 15():1381308. PubMed ID: 38745670
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Comprehensive analysis of the efficacy and safety of car T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: a systematic review and meta-analysis.
    Willyanto SE; Alimsjah YA; Tanjaya K; Tuekprakhon A; Pawestri AR
    Ann Med; 2024 Dec; 56(1):2349796. PubMed ID: 38738799
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Recent advances in car-T cell therapy for acute myeloid leukaemia.
    Gao C; Li X; Xu Y; Zhang T; Zhu H; Yao D
    J Cell Mol Med; 2024 May; 28(9):e18369. PubMed ID: 38712978
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Off-the-shelf car-T cell therapies for relapsed or refractory B-cell malignancies: latest update from ASH 2023 annual meeting.
    Kang Y; Li C; Mei H
    J Hematol Oncol; 2024 May; 17(1):29. PubMed ID: 38711046
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Combination of venetoclax and azacitidine in relapsed/refractory acute B-cell lymphoblastic leukemia: a case series from a single center.
    Hao Z; Fei Y; Chen J; Huang S; Wang L; Yu Y; Bian M; Si Y; Zhang X; Yang X; Zhang B; Wan Y; Zhang Y; Lin G
    Hematology; 2024 Dec; 29(1):2344998. PubMed ID: 38666535
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Infectious complications in pediatric patients undergoing CD19+CD22+ chimeric antigen receptor T-cell therapy for relapsed/refractory B-lymphoblastic leukemia.
    Wu X; Cao Z; Chen Z; Wang Y; He H; Xiao P; Hu S; Lu J; Li B
    Clin Exp Med; 2024 Apr; 24(1):87. PubMed ID: 38662121
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Overcoming the challenges encountered in car-T therapy: latest updates from the 2023 ASH annual conference.
    Zhang T; Zhang Y; Wei J
    Front Immunol; 2024; 15():1389324. PubMed ID: 38660304
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Supportive care measures for bispecific T-cell engager therapies in haematological malignancies.
    Chen LY; Kothari J
    Curr Opin Support Palliat Care; 2024 Jun; 18(2):92-99. PubMed ID: 38652455
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Implantable car T cell factories enhance solid tumor treatment.
    Pandit S; Agarwalla P; Song F; Jansson A; Dotti G; Brudno Y
    Biomaterials; 2024 Jul; 308():122580. PubMed ID: 38640784
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells.
    Dabkowska A; Domka K; Firczuk M
    Front Immunol; 2024; 15():1363102. PubMed ID: 38638442
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. [CHIMERIC ANTIGEN RECEPTOR T CELLS (car-T CELLS) THERAPY FOR B-CELL HEMATOLOGICAL MALIGNANCIES - FROM THE ISRAELI SOCIETY OF HEMATOLOGY AND TRANSFUSION MEDICINE].
    Greenbaum U; Yehudai-Ofir D; Beyar Katz O; Shargian L; Jacoby E; Grisaru S; Zuckerman T; Ram R; Avigdor A
    Harefuah; 2024 Apr; 163(4):236-243. PubMed ID: 38616634
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. The dilemmas and possible solutions for car-T cell therapy application in solid tumors.
    Wang L; Zhang L; Dunmall LC; Wang YY; Fan Z; Cheng Z; Wang Y
    Cancer Lett; 2024 Jun; 591():216871. PubMed ID: 38604310
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. FOXO1 enhances car T cell stemness, metabolic fitness and efficacy.
    Chan JD; Scheffler CM; Munoz I; Sek K; Lee JN; Huang YK; Yap KM; Saw NYL; Li J; Chen AXY; Chan CW; Derrick EB; Todd KL; Tong J; Dunbar PA; Li J; Hoang TX; de Menezes MN; Petley EV; Kim JS; Nguyen D; Leung PSK; So J; Deguit C; Zhu J; House IG; Kats LM; Scott AM; Solomon BJ; Harrison SJ; Oliaro J; Parish IA; Quinn KM; Neeson PJ; Slaney CY; Lai J; Beavis PA; Darcy PK
    Nature; 2024 May; 629(8010):201-210. PubMed ID: 38600376
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Safety and efficacy of chimeric antigen receptor T-cell therapy for acute myeloid leukemia: A subgroup based meta-analysis.
    Morsy MM; Azzam AY; Elamin O; Elswedy A; Nashwan AJ
    Leuk Res; 2024 May; 140():107498. PubMed ID: 38582045
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens.
    Xiong ZY; Shen YJ; Zhang SZ; Zhu HH
    Hematology; 2024 Dec; 29(1):2335856. PubMed ID: 38581291
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. TRBC1-targeting antibody-drug conjugates for the treatment of T cell cancers.
    Nichakawade TD; Ge J; Mog BJ; Lee BS; Pearlman AH; Hwang MS; DiNapoli SR; Wyhs N; Marcou N; Glavaris S; Konig MF; Gabelli SB; Watson E; Sterling C; Wagner-Johnston N; Rozati S; Swinnen L; Fuchs E; Pardoll DM; Gabrielson K; Papadopoulos N; Bettegowda C; Kinzler KW; Zhou S; Sur S; Vogelstein B; Paul S
    Nature; 2024 Apr; 628(8007):416-423. PubMed ID: 38538786
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. [Efficacy and safety of chimeric antigen receptor T-cell therapy followed by allogeneic hematopoietic stem cell transplantation in 21 patients with Ph-like acute lymphoblastic leukemia].
    Dai HP; Shen HJ; Li Z; Cui W; Cui QY; Li MY; Chen SF; Zhu MQ; Wu DP; Tang XW
    Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):35-40. PubMed ID: 38527836
    [No Abstract]    [Full Text] [Related]  

  • 18. [Effect of early tocilizumab intervention on patients with cytokine release syndrome following chimeric antigen receptor T cell therapy].
    Zhou LL; Ye SG; Li P; Tang XC; Liang AB
    Zhonghua Xue Ye Xue Za Zhi; 2023 Dec; 44(12):1022-1026. PubMed ID: 38503526
    [No Abstract]    [Full Text] [Related]  

  • 19. Practice guideline: Preparation for car T-cell therapy in children and young adults with B-acute lymphoblastic leukaemia.
    Mishra AK; Burridge S; Espuelas MO; O'Reilly M; Cummins M; Nicholson E; Wheldon S; Bonney D; Shenton G; Marks DI; Amrolia PJ; Hough R; Ghorashian S
    Br J Haematol; 2024 May; 204(5):1687-1696. PubMed ID: 38488312
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Case report: Two pediatric cases of long-term leukemia-free survival with relapsed acute T-lymphoblastic leukemia treated with donor CD7 car-T cells bridging to haploidentical stem cell transplantation.
    Song Y; Liu Z; Wang Q; Gao K; Wu T
    Front Immunol; 2024; 15():1333037. PubMed ID: 38481998
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 67.